The combination of mesenchymal stem cells and a bone scaffold in the treatment of vertebral body defects

Vaněček, Václav; Klíma, Karel; Kohout, A; Foltán, René; Jiroušek, Ondřej; Šedý, Jiří; Štulík, J; Syková, Eva; Jendelová, Pavla

doi:10.1007/s00586-013-2991-2

Cited by 24 publications

(28 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The good manufacturing practice production of MSCs has been previously described [ 6 ]. Following State Institute for Drug Control and the Local Ethics Committee approval, nine human participants, having given informed consent, underwent a bone marrow aspiration of the anterior ilium under local anesthetic (EudraCT number 2012-005599-33 ).…”

Section: Methodsmentioning

confidence: 99%

“…Based on the results of preclinical studies, hydroxyapatite and calcium phosphate are ideal substrates for use as a matrix due to their excellent osteoconductive properties [ 4 – 6 ]. Usually, when using hydroxyapatite, it is combined with either β -tricalcium phosphate, resulting in biphasic calcium phosphate, or biodegradable polymers, resulting in composite biomaterials.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Utilizing Autologous Multipotent Mesenchymal Stromal Cells andβ-Tricalcium Phosphate Scaffold in Human Bone Defects: A Prospective, Controlled Feasibility Trial

Šponer

Filip

Kucera

et al. 2016

BioMed Research International

Self Cite

View full text Add to dashboard Cite

The purpose of this prospective controlled study was to compare healing quality following the implantation of ultraporous β-tricalcium phosphate, containing either expanded autologous mesenchymal stromal cells (trial group, 9 patients) or β-tricalcium phosphate alone (control group, 9 patients), into femoral defects during revision total hip arthroplasty. Both groups were assessed using the Harris Hip Score, radiography, and DEXA scanning at 6 weeks and 3, 6, and 12 months postoperatively. A significant difference in the bone defect healing was observed between both groups of patients (P < 0.05). In the trial group, trabecular remodeling was found in all nine patients and in the control group, in 1 patient only. Whereas, over the 12-month follow-up period, no significant difference was observed between both groups of patients in terms of the resorption of β-tricalcium phosphate, the significant differences were documented in the presence of radiolucency and bone trabeculation through the defect (P < 0.05). Using autologous mesenchymal stromal cells combined with a β-tricalcium phosphate scaffold is a feasible, safe, and effective approach for management of bone defects with compromised microenvironment. The clinical trial was registered at the EU Clinical Trials Register before patient recruitment has begun (EudraCT number 2012-005599-33).

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Utilizing Autologous Multipotent Mesenchymal Stromal Cells andβ-Tricalcium Phosphate Scaffold in Human Bone Defects: A Prospective, Controlled Feasibility Trial

Šponer

Filip

Kucera

et al. 2016

BioMed Research International

Self Cite

View full text Add to dashboard Cite

show abstract

“…Stem cells were also used in a bone defect in the second lumbar vertebra. The defect was made by a microdrill using a ventral approach and sized 2 × 5 × 1.5 mm [206].…”

Section: Ratsmentioning

confidence: 99%

Preclinical testing of drug delivery systems to bone

Griensven

2015

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

“…Both micro-CT scans and histological examinations found that the HA scaffold seeded with 5 million MSCs showed positive results compared to the others. The inflammation was negligible and the osteoinductivity was remarkably higher than that with the scaffold alone, which is evident from the increase in bone formation [ 41 ].…”

Section: Recent Advances In Skeletal Disease/injury Treatmentmentioning

confidence: 99%

Recent Advances in Hydroxyapatite Scaffolds Containing Mesenchymal Stem Cells

Michel

Penna

Kochen

et al. 2015

Stem Cells International

View full text Add to dashboard Cite

Modern day tissue engineering and cellular therapies have gravitated toward using stem cells with scaffolds as a dynamic modality to aid in differentiation and tissue regeneration. Mesenchymal stem cells (MSCs) are one of the most studied stem cells used in combination with scaffolds. These cells differentiate along the osteogenic lineage when seeded on hydroxyapatite containing scaffolds and can be used as a therapeutic option to regenerate various tissues. In recent years, the combination of hydroxyapatite and natural or synthetic polymers has been studied extensively. Due to the interest in these scaffolds, this review will cover the wide range of hydroxyapatite containing scaffolds used with MSCs for in vitro and in vivo experiments. Further, in order to maintain a progressive scope of the field this review article will only focus on literature utilizing adult human derived MSCs (hMSCs) published in the last three years.

show abstract

The combination of mesenchymal stem cells and a bone scaffold in the treatment of vertebral body defects

Abstract: MSCs in combination with a hydroxyapatite scaffold improved the repair of a model bone defect and might represent a safe and effective alternative in the treatment of vertebral bone defects.

Cited by 24 publications

References 40 publications

Utilizing Autologous Multipotent Mesenchymal Stromal Cells andβ-Tricalcium Phosphate Scaffold in Human Bone Defects: A Prospective, Controlled Feasibility Trial

Utilizing Autologous Multipotent Mesenchymal Stromal Cells andβ-Tricalcium Phosphate Scaffold in Human Bone Defects: A Prospective, Controlled Feasibility Trial

Preclinical testing of drug delivery systems to bone

Recent Advances in Hydroxyapatite Scaffolds Containing Mesenchymal Stem Cells

Contact Info

Product

Resources

About